Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1982 1
1988 2
1989 1
1990 2
1993 4
1994 9
1995 7
1996 7
1997 13
1998 13
1999 22
2000 35
2001 31
2002 22
2003 25
2004 38
2005 49
2006 63
2007 57
2008 66
2009 92
2010 122
2011 146
2012 196
2013 182
2014 219
2015 205
2016 196
2017 214
2018 193
2019 218
2020 250
2021 316
2022 267
2023 235
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

3,172 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Doki Y, et al. Among authors: kim hr. N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380. N Engl J Med. 2022. PMID: 35108470 Clinical Trial.
A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy.
Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, Lam SZ, Guo J, Tang E, Zhang Y, Wang G, Dai X, Du Y, Kim HR, Cao H, Errami Y, Clark P, Bersenev A, Montgomery RR, Chen S. Ye L, et al. Among authors: kim hr. Cell Metab. 2022 Apr 5;34(4):595-614.e14. doi: 10.1016/j.cmet.2022.02.009. Epub 2022 Mar 10. Cell Metab. 2022. PMID: 35276062 Free PMC article.
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. Camidge DR, et al. Among authors: kim hr. J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16. J Thorac Oncol. 2021. PMID: 34537440 Free article. Clinical Trial.
Musculoskeletal complications in patients with diabetes mellitus.
Choi JH, Kim HR, Song KH. Choi JH, et al. Among authors: kim hr. Korean J Intern Med. 2022 Nov;37(6):1099-1110. doi: 10.3904/kjim.2022.168. Epub 2022 Oct 27. Korean J Intern Med. 2022. PMID: 36300322 Free PMC article. Review.
ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.
Hong Y, Walling BL, Kim HR, Serratelli WS, Lozada JR, Sailer CJ, Amitrano AM, Lim K, Mongre RK, Kim KD, Capece T, Lomakina EB, Reilly NS, Vo K, Gerber SA, Fan TC, Yu AL, Oakes PW, Waugh RE, Jun CD, Reagan PM, Kim M. Hong Y, et al. Among authors: kim hr. Nat Immunol. 2023 Jun;24(6):1007-1019. doi: 10.1038/s41590-023-01498-x. Epub 2023 Apr 17. Nat Immunol. 2023. PMID: 37069398 Free PMC article.
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK. Le X, et al. Among authors: kim hr. Clin Cancer Res. 2022 Mar 15;28(6):1117-1126. doi: 10.1158/1078-0432.CCR-21-2733. Clin Cancer Res. 2022. PMID: 34789481 Free PMC article. Clinical Trial.
Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination.
Huh HD, Sub Y, Oh J, Kim YE, Lee JY, Kim HR, Lee S, Lee H, Pak S, Amos SE, Vahala D, Park JH, Shin JE, Park SY, Kim HS, Roh YH, Lee HW, Guan KL, Choi YS, Jeong J, Choi J, Roe JS, Gee HY, Park HW. Huh HD, et al. Among authors: kim hr. Mol Cancer. 2023 Mar 30;22(1):63. doi: 10.1186/s12943-023-01753-7. Mol Cancer. 2023. PMID: 36991428 Free PMC article.
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR. Ahn MJ, et al. Among authors: kim hr. Clin Lung Cancer. 2022 Dec;23(8):720-730. doi: 10.1016/j.cllc.2022.07.008. Epub 2022 Jul 21. Clin Lung Cancer. 2022. PMID: 36038416 Free article. Clinical Trial.
3,172 results